07:00 , Jul 1, 2013 |  BC Week In Review  |  Clinical News

Antisense Therapeutics, Isis Pharmaceuticals preclinical data

In mice, ATL1103 for 3 weeks suppressed growth hormone receptor RNA expression and significantly reduced downstream insulin-like growth factor-1 ( IGF-1 ) RNA expression in the liver vs. Somavert pegvisomant and octreotide. Additionally, ATL1103 plus...
08:00 , Feb 18, 2013 |  BioCentury  |  Strategy

Delivering on the upside

In 2008 the new CEO of Chiasma Inc. refocused the drug delivery company on product development with an eye to capturing more of the upside from the investment in its formulation technology. On Monday this...
07:00 , Sep 6, 2010 |  BioCentury  |  Strategy

Laying siege

sanofi-aventis Group made clear in its conference call last week that it's in no hurry to complete its proposed acquisition of Genzyme Corp. - with the obvious implication that time is on its side. If...
08:00 , Dec 7, 2009 |  BioCentury  |  Strategy

Pfizer Inverts Itself for Gaucher's

Taliglucerase alfa from Protalix Biotherapeutics Inc. will not be Pfizer Inc. 's first foray into Orphan diseases. But it will require the pharma to turn its commercial approach upside down, especially if it aims to...
07:00 , Jun 30, 2008 |  BioCentury  |  Strategy

Pfizer’s biotherapeutic pipeline

Pfizer’s biotherapeutic pipeline...
08:00 , Jan 29, 2007 |  BC Week In Review  |  Company News

Ipsen, Erasmus Medical Center deal

Erasmus assigned international patent application no. WO 06/108667 to IPN. The patent application claims the co-administration of a monthly long-acting somatostatin analog with a weekly subcutaneous pegvisomant growth hormone antagonist to treat acromegaly. Erasmus will...
08:00 , Feb 6, 2006 |  BioCentury  |  Strategy

Nektar's pipeline

Nektar's pipeline...
08:00 , Feb 2, 2004 |  BioCentury  |  Politics, Policy & Law

Europe's orphan medicines

Europe's orphan medicines...
07:00 , Jun 9, 2003 |  BC Week In Review  |  Company News

Akzo Nobel NV, Pfizer deal

AKZOY subsidiary Diosynth Biotechnology (Oss, the Netherlands) will supply PFE with the active ingredient in PFE's Somavert, a recombinant protein for treating certain growth hormone disorders in patients with inadequate response to other treatments. Somavert...
07:00 , Jun 2, 2003 |  BC Extra  |  Company News

Akzo Nobel, Pfizer supply deal

AKZOY subsidiary Diosynth Biotechnology (Oss, the Netherlands) will supply PFE with the active ingredient in PFE's Somavert, a therapeutic recombinant protein for treating certain growth hormone disorders in patients with inadequate response to other treatments....